Ai‐Min Hui
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Papers in
- Hematology 19
- Multiple Myeloma Research and Treatments 16
-
- Hepatocellular Carcinoma Treatment and Prognosis 4
- Co-authors
- Masatoshi Makuuchi (12 shared papers)Tadatoshi Takayama (13 shared papers)Xin Li (6 shared papers)Michiie Sakamoto (3 shared papers)Yae Kanai (3 shared papers)Neeraj Gupta (15 shared papers)Setsuo Hirohashi (2 shared papers)Karthik Venkatakrishnan (7 shared papers)
- Journals
- Blood (15 papers)Hepatology (4 papers)Life (2 papers)Investigational New Drugs (2 papers)Advances in Therapy (2 papers)
- Partner nations
- United StatesChinaJapan
In The Last Decade
Ai‐Min Hui
74 papers receiving 2.1k citations
Peers
Comparison fields: 5 of 61
- Hematology 438
- Hepatology 230
- Radiology, Nuclear Medicine and Imaging 223
- Molecular Biology 376
- Infectious Diseases 110
Countries citing papers authored by Ai‐Min Hui
This map shows the geographic impact of Ai‐Min Hui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ai‐Min Hui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ai‐Min Hui more than expected).
Fields of papers citing papers by Ai‐Min Hui
This network shows the impact of papers produced by Ai‐Min Hui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ai‐Min Hui. The network helps show where Ai‐Min Hui may publish in the future.
Co-authors
The 25 scholars most cited alongside Ai‐Min Hui, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 77 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 251 | |
| 2 | 2000 | 111 | |
| 3 | 2021 | 111 | |
| 4 | 1996 | 103 | |
| 5 | 1999 | 98 | |
| 6 | 2004 | 90 | |
| 7 | 1997 | 82 | |
| 8 | Cell cycle regulators and human hepatocarcinogenesis. | 1999 | 62 |
| 9 | 2017 | 60 | |
| 10 | 2008 | 58 | |
| 11 | 2022 | 58 | |
| 12 | 1999 | 54 | |
| 13 | 2015 | 54 | |
| 14 | 2014 | 52 | |
| 15 | 2022 | 47 | |
| 16 | Overexpression of retinoblastoma protein predicts decreased survival and correlates with loss of p16INK4 protein in gallbladder carcinomas. | 2000 | 46 |
| 17 | 2016 | 46 | |
| 18 | Cyclin D1 overexpression is a critical event in gallbladder carcinogenesis and independently predicts decreased survival for patients with gallbladder carcinoma. | 2000 | 41 |
| 19 | 1999 | 39 | |
| 20 | 2016 | 38 |
About Ai‐Min Hui
Ai‐Min Hui is a scholar working on Hematology, Hepatology, Infectious Diseases, Molecular Biology and Surgery, having authored 77 papers that have together received 2.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers), SARS-CoV-2 and COVID-19 Research (6 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers), Epigenetics and DNA Methylation (3 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Cancer-related Molecular Pathways (2 papers). The work is most often cited by research in Hematology (438 citations), Hepatology (230 citations), Radiology, Nuclear Medicine and Imaging (223 citations), Molecular Biology (376 citations) and Infectious Diseases (110 citations). Ai‐Min Hui has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Masatoshi Makuuchi, Tadatoshi Takayama, Xin Li, Michiie Sakamoto, Yae Kanai, Neeraj Gupta, Setsuo Hirohashi, Karthik Venkatakrishnan, Lin Sun and Safiye Osman. Their work appears in journals such as Blood, Hepatology, Life, Investigational New Drugs and Advances in Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.